Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BriaCell Therapeutics ( (TSE:BCT) ) has provided an update.
BriaCell Therapeutics has announced promising results from its ongoing Phase 2 study of Bria-IMT™ in combination with a checkpoint inhibitor for advanced metastatic breast cancer patients. A patient with ‘eye-bulging’ breast cancer, who had previously failed eight treatment regimens, has shown a complete and sustained resolution of brain metastasis and continued regression of an orbital tumor for over 18 months. This development underscores the potential of Bria-IMT to provide durable immunotherapeutic benefits for late-stage breast cancer patients with brain metastases, offering hope for improved outcomes.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$15.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care.
Average Trading Volume: 19,849
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$27.1M
Find detailed analytics on BCT stock on TipRanks’ Stock Analysis page.